TY - JOUR
T1 - Omega-3 fatty acids and domain-specific cognitive aging
T2 - Secondary analyses of data from WHISCA
AU - Ammann, Eric M.
AU - Pottala, James V.
AU - Harris, William S.
AU - Espeland, Mark A.
AU - Wallace, Robert
AU - Denburg, Natalie L.
AU - Carnahan, Ryan M.
AU - Robinson, Jennifer G.
PY - 2013/10/22
Y1 - 2013/10/22
N2 - Objective: To test the hypothesis that higher levels of red blood cell (RBC) docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) have a protective association with domain-specific cognitive function in women aged 65 years and older. Methods: A total of 2,157 women with normal cognition enrolled in a clinical trial of postmenopausal hormone therapy were followed with annual cognitive testing for a median of 5.9 years. In this retrospective cohort study, we assessed the relationship between prerandomization RBC DHA + EPA levels and a) cognitive measures at baseline, and b) cognitive change over time. Endpoints were composite cognitive function and performance in 7 cognitive domains: fine motor speed, verbal memory, visual memory, spatial ability, verbal knowledge, verbal fluency, and working memory. Results: After adjustment for demographic, clinical, and behavioral characteristics, no significant (p < 0.01) cross-sectional cognitive differences were found between women in the high and low DHA + EPA tertiles at the time of the first annual cognitive battery. In addition, no significant (p < 0.01) differences were found between the high and low DHA + EPA tertiles in the rate of cognitive change over time. Conclusions: We did not find an association between RBC DHA + EPA levels and age-associated cognitive decline in a cohort of older, dementia-free women.
AB - Objective: To test the hypothesis that higher levels of red blood cell (RBC) docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) have a protective association with domain-specific cognitive function in women aged 65 years and older. Methods: A total of 2,157 women with normal cognition enrolled in a clinical trial of postmenopausal hormone therapy were followed with annual cognitive testing for a median of 5.9 years. In this retrospective cohort study, we assessed the relationship between prerandomization RBC DHA + EPA levels and a) cognitive measures at baseline, and b) cognitive change over time. Endpoints were composite cognitive function and performance in 7 cognitive domains: fine motor speed, verbal memory, visual memory, spatial ability, verbal knowledge, verbal fluency, and working memory. Results: After adjustment for demographic, clinical, and behavioral characteristics, no significant (p < 0.01) cross-sectional cognitive differences were found between women in the high and low DHA + EPA tertiles at the time of the first annual cognitive battery. In addition, no significant (p < 0.01) differences were found between the high and low DHA + EPA tertiles in the rate of cognitive change over time. Conclusions: We did not find an association between RBC DHA + EPA levels and age-associated cognitive decline in a cohort of older, dementia-free women.
UR - http://www.scopus.com/inward/record.url?scp=84888221896&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84888221896&partnerID=8YFLogxK
U2 - 10.1212/WNL.0b013e3182a9584c
DO - 10.1212/WNL.0b013e3182a9584c
M3 - Article
C2 - 24068783
AN - SCOPUS:84888221896
SN - 0028-3878
VL - 81
SP - 1484
EP - 1491
JO - Neurology
JF - Neurology
IS - 17
ER -